22 May 2013
Keywords: high-dose, copaxone, effective, rrms, trial, israeli, drugmaker
Article | 17 April 2006
Israeli drugmaker Teva Pharmaceutical says that data from a Phase II trial of its multiple sclerosis drug Copaxone (glatiramer acetate
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 April 2006
10 April 2006
21 May 2013
© 2013 thepharmaletter.com